Skip to main content
Tonix Pharmaceuticals Holding Corp. logo

Tonix Pharmaceuticals Holding Corp. — Investor Relations & Filings

Ticker · TNXP ISIN · US8902608392 LEI · 529900ACPKP9QW20GX48 US Manufacturing
Open in API
Filings indexed 1,422 across all filing types
Latest filing 2026-06-08 Regulatory Filings
Country US United States of America
Listing US TNXP

About Tonix Pharmaceuticals Holding Corp.

https://www.tonixpharma.com/

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company developing therapeutics and vaccines for human diseases. The company's pipeline addresses complex, chronic conditions in several key areas: central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Key CNS programs target conditions such as acute stress disorder. The immunology portfolio includes candidates for preventing organ transplant rejection, managing autoimmune conditions, and immuno-oncology. Its infectious disease efforts focus on biodefense, utilizing a live virus vaccine platform to develop vaccines for mpox and smallpox. The company is also advancing treatments for rare diseases like Prader-Willi Syndrome. All of Tonix's product candidates are investigational and have not been approved for any indication.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 85% confidence The document is a U.S. SEC Form 8-K (Current Report) disclosing Item 7.01 Regulation FD Disclosure and Item 8.01 Other Events. It is a routine regulatory filing rather than an earnings release, financial report, or management presentation. As it does not fit into specialized categories (e.g., ER, IR, MDA) and primarily serves as a compliance filing under the Exchange Act, it is classified as a general Regulatory Filing (RNS).
2026-06-08 English
8-K
Regulatory Filings Classification · 94% confidence The document is a SEC Form 8-K (“Current Report”) disclosing a Regulation FD event and other non-financial events (publication of a clinical manuscript and related press release). It does not contain earnings data, a call transcript, management changes, dividend or M&A information, or substantive financial statements. It is a general regulatory filing about an event, so it falls into the fallback category ‘Regulatory Filings’ (RNS).
2026-05-27 English
CURRENT REPORT
Regulatory Filings Classification · 90% confidence The document is a U.S. SEC Form 8-K “Current Report” disclosing a Regulation FD presentation and other events. It does not contain actual financial statements or earnings data, nor is it a presentation slide deck itself; rather, it is a general regulatory filing. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-15 English
8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)
Earnings Release Classification · 88% confidence The document is a Form 8-K current report filed under Item 2.02 “Results of Operations and Financial Condition” announcing its quarterly operating results (press release attached as Exhibit 99.01). This corresponds to an earnings release (initial announcement of periodical financial results). Q1 2026
2026-05-11 English
10-Q - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)
Interim / Quarterly Report
2026-05-11 English
8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a current report on Form 8-K, containing Item 5.07 “Submission of Matters to a Vote of Security Holders,” which details the voting results for director elections, auditor ratification, share split authorization, and stock incentive plan approval. This matches the definition of Declaration of Voting Results & Voting Rights Announcements (DVA).
2026-05-07 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.